The Methylation Effect in Medicinal Chemistry

UCSF Chimera—A visualization system for exploratory research and analysis

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828

Regulation of the mevalonate pathway

Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243

Partition coefficients and their uses

Leo, A., Hansch, C., & Elkins, D. (1971) · Chemical Reviews · doi:10.1021/cr60274a001 · Cited by 4,540

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389

Principles of Nucleic Acid Structure

Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150

Promotion of microtubule assembly in vitro by taxol

SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967

Stereochemistry of organic compounds

Peakman, T. M. (1995) · Geochimica et Cosmochimica Acta · doi:10.1016/0016-7037(95)90151-5 · Cited by 2,920

Actions of caffeine in the brain with special reference to factors that contribute to its widespread use

Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624

Compendium of chemical terminology

Gold, V. (1987) · Cited by 2,525

Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes

Meunier, B., de Visser, S. P., & Shaik, S. (2004) · Chemical Reviews · doi:10.1021/cr020443g · Cited by 2,398

Definition and Antagonism of Histamine H2-receptors

BLACK, J. W., DUNCAN, W. A. M., DURANT, C. J., GANELLIN, C. R., & PARSONS, E. M. (1972) · Nature · doi:10.1038/236385a0 · Cited by 2,259

The Effect of Structure upon the Reactions of Organic Compounds. Benzene Derivatives

Hammett, L. P. (1937) · Journal of the American Chemical Society · doi:10.1021/ja01280a022 · Cited by 2,249

Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)

Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960803q · Cited by 1,965

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,956

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917

ARACHIDONIC ACID METABOLISM

Needleman, P., Truk, J., Jakschik, B. A., Morrison, A. R., & Lefkowith, J. B. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.000441 · Cited by 1,807

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757

Medicinal natural products: A biosynthetic approach

(2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01302-2 · Cited by 1,700

Structural mechanism for statin inhibition of HMG-CoA reductase

Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

Alberts, A. W., Chen, J., Kuron, G., Hunt, V, Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,628

Nomenclature and classification of purinoceptors.

Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., & Williams, M. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06782-1 · Cited by 1,585

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L., & Isakson, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12013 · Cited by 1,551

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis

Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519

Load Independence of the Instantaneous Pressure-Volume Ratio of the Canine Left Ventricle and Effects of Epinephrine and Heart Rate on the Ratio

SUGA, H., SAGAWA, K., & SHOUKAS, A. A. (1973) · Circulation Research · doi:10.1161/01.res.32.3.314 · Cited by 1,502

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492

Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects

Nehlig, A., Daval, J.-L., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,461

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389

A New Substituent Constant, π, Derived from Partition Coefficients

Fujita, T., Iwasa, J., & Hansch, C. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01077a028 · Cited by 1,370

Bioisosterism: A Rational Approach in Drug Design

Patani, G. A., & LaVoie, E. J. (1996) · Chemical Reviews · doi:10.1021/cr950066q · Cited by 1,328

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310

Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297

Enzymatic O-methylation of epinephrine and other catechols

Axelrod, J., & Tomchick, R. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64731-3 · Cited by 1,283

Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products

Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281

Aromatic substituent constants for structure-activity correlations

Hansch, C., Leo, A., Unger, S. H., Kim, K. H., Nikaitani, D., & Lien, E. J. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00269a003 · Cited by 1,262

Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling

Conti, M., & Beavo, J. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.150444 · Cited by 1,183

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036

Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics

Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979

Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs

Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D., & Russell, R. I. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209103271101 · Cited by 958

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943

Purine and pyrimidine receptors

Burnstock, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6497-0 · Cited by 929

Quantitative approach to biochemical structure-activity relationships

Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918

A View of the Hydrophobic Effect

Southall, N. T., Dill, K. A., & Haymet, A. D. J. (2002) · The Journal of Physical Chemistry B · doi:10.1021/jp015514e · Cited by 913

International Union of Pharmacology. XIII. Classification of Histamine Receptors

Hill, S. J., Ganellin, C. R., Timmerman, H., Schwartz, J. C., Shankley, N. P., Young, J. M., Schunack, W., Levi, R., & Haas, H. L. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01328-0 · Cited by 899

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875

Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

Lugnier, C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.003 · Cited by 870

Some Relations between Reaction Rates and Equilibrium Constants.

Hammett, L. P. (1935) · Chemical Reviews · doi:10.1021/cr60056a010 · Cited by 866

BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843

New insights into the mode of action of anti-inflammatory drugs

Vane, J. R., & Botting, R. M. (1995) · Inflammation Research · doi:10.1007/bf01630479 · Cited by 838

Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity

Endo, A., Kuroda, M., & Tanzawa, K. (1976) · FEBS Letters · doi:10.1016/0014-5793(76)80996-9 · Cited by 794

Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond

Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773

The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans

P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772

THE CATALYTIC MECHANISM AND STRUCTURE OF THYMIDYLATE SYNTHASE

Carreras, C. W., & Santi, D. V. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003445 · Cited by 768

The Chemical and Biological Versatility of Riboflavin

Massey, V. (2000) · Biochemical Society Transactions · doi:10.1042/0300-5127:0280283 · Cited by 751

Regulation of HMG-CoA Reductase

RODWELL, V. W., NORDSTROM, J. L., & MITSCHELEN, J. J. (1976) · Advances in Lipid Research · doi:10.1016/b978-0-12-024914-5.50008-5 · Cited by 746

Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors.

Mosberg, H. I., Hurst, R., Hruby, V. J., Gee, K., Yamamura, H. I., Galligan, J. J., & Burks, T. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.19.5871 · Cited by 740

Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism

Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P., & Desmeules, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041888 · Cited by 702

Adenosine receptors and behavioral actions of methylxanthines.

Snyder, S. H., Katims, J. J., Annau, Z., Bruns, R. F., & Daly, J. W. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.5.3260 · Cited by 694

Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design

Lima, L., & Barreiro, E. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053363540 · Cited by 672

Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.

Raynor, K., Kong, H., Chen, Y., Yasuda, K., Yu, L., Bell, G. I., & Reisine, T. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09932-8 · Cited by 665

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2

Talley, J. J., Brown, D. L., Carter, J. S., Graneto, M. J., Koboldt, C. M., Masferrer, J. L., Perkins, W. E., Rogers, R. S., Shaffer, A. F., Zhang, Y. Y., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990577v · Cited by 638

Putting chirality to work: the strategy of chiral switches

Agranat, I., Caner, H., & Caldwell, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd915 · Cited by 637

Purification and Properties of Phenylethanolamine-N-methyl Transferase

Axelrod, J. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)83758-4 · Cited by 623

Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase

Fellenius, E., Berglindh, T., Sachs, G., Olbe, L., Elander, B., Sjöstrand, S.-E., & Wallmark, B. (1981) · Nature · doi:10.1038/290159a0 · Cited by 619

Relating Protein Motion to Catalysis

Hammes-Schiffer, S., & Benkovic, S. J. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142800 · Cited by 610

The CH/π interaction: Significance in molecular recognition

Nishio, M., Umezawa, Y., Hirota, M., & Takeuchi, Y. (1995) · Tetrahedron · doi:10.1016/0040-4020(94)01066-9 · Cited by 606

SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold

Martin, J. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00391-3 · Cited by 578

S-ADENOSYLMETHIONINE; A NEW INTERMEDIATE FORMED ENZYMATICALLY FROM l-METHIONINE AND ADENOSINETRIPHOSPHATE

Cantoni, G. L. (1953) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66148-4 · Cited by 571

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569

Antiarrhythmic Agents: The Modulated Receptor Mechanism of Action of Sodium and Calcium Channel-Blocking Drugs

Hondeghem, L. M., & Katzung, B. G. (1984) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.24.040184.002131 · Cited by 565

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554

Medicinal Natural Products: A Biosynthetic Approach

Dewick, P. M. (2001) · Wiley eBooks · doi:10.1002/0470846275 · Cited by 541

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4- dimethyl-1 H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521

Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings

Dalvie, D. K., Kalgutkar, A. S., Khojasteh-Bakht, S. C., Obach, R. S., & O'Donnell, J. P. (2002) · Chemical Research in Toxicology · doi:10.1021/tx015574b · Cited by 518

COX-2 and beyond: approaches to prostaglandin inhibition in human disease

FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518

Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor

Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484

The benzodiazepine story

Sternbach, L. H. (1979) · Journal of Medicinal Chemistry · doi:10.1021/jm00187a001 · Cited by 448

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434

Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

Davies, N. M., McLachlan, A. J., Day, R. O., & Williams, K. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038030-00003 · Cited by 424

A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole

Olbe, L., Carlsson, E., & Lindberg, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1010 · Cited by 418

Discovery of a novel Raf kinase inhibitor.

Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.

McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413

A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors

Gierse, J. K., McDonald, J. J., Hauser, S. D., Rangwala, S. H., Koboldt, C. M., & Seibert, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.26.15810 · Cited by 410

The Distribution and Properties of a Histamine-methylating Enzyme

Brown, D. D., Tomchick, R., & Axelrod, J. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69701-7 · Cited by 374

Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum

Brown, A. G., Smale, T. C., King, T. J., Hasenkamp, R., & Thompson, R. H. (1976) · Journal of the Chemical Society, Perkin Transactions 1 · doi:10.1039/p19760001165 · Cited by 360

Folate and DNA Methylation: A Mechanistic Link between Folate Deficiency and Colorectal Cancer?

Kim, Y.-I. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.511.13.4 · Cited by 350

Synthetic Analgesics: Stereochemical Considerations

Beckett, A. H., & Casy, A. F. (1954) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1954.tb11033.x · Cited by 334

Molecular Mechanisms of Thiamine Utilization.

Singleton., C., & Martin, P. (2001) · Current Molecular Medicine · doi:10.2174/1566524013363870 · Cited by 321

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313

Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications

Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi002 · Cited by 310

The mechanism of action of the antisecretory agent omeprazole

Lindberg, P., Nordberg, P., Alminger, T., Braendstroem, A., & Wallmark, B. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00158a001 · Cited by 305

Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonist

Rinaldi-Carmona, M., Barth, F., Héaulme, M., Alonso, R., Shire, D., Congy, C., Soubrié, P., Brelière, J.-C., & Le Fur, G. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00174-5 · Cited by 303

Behavioral and neurochemical effects of acute and daily cocaine administration in rats.

Kalivas, P. W., Duffy, P., DuMars, L. A., & Skinner, C. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22646-5 · Cited by 302

ZD1839 (???Iressa???)*,??? as an Anticancer Agent

Baselga, J., & Averbuch, S. D. (2000) · Drugs · doi:10.2165/00003495-200060001-00004 · Cited by 301

Caffeine: a well known but little mentioned compound in plant science

Ashihara, H., & Crozier, A. (2001) · Trends in Plant Science · doi:10.1016/s1360-1385(01)02055-6 · Cited by 300

The Immunosuppressive Metabolite of Leflunomide Is a Potent Inhibitor of Human Dihydroorotate Dehydrogenase

Davis, J. P., Cain, G. A., Pitts, W. J., Magolda, R. L., & Copeland, R. A. (1996) · Biochemistry · doi:10.1021/bi952168g · Cited by 293

Chemistry of Covalent Inhibition of the Gastric (H+, K+)-ATPase by Proton Pump Inhibitors

Shin, J. M., Cho, Y. M., & Sachs, G. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049607w · Cited by 283

4-Aminoquinolines—Past, present, and future; A chemical perspective

O'Neill, P. M., Bray, P. G., Hawley, S. R., Ward, S. A., & Park, B. K. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00084-3 · Cited by 282

The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.

Moore, N. A., Tye, N. C., Axton, M. S., & Risius, F. C. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10792-1 · Cited by 278

The pharmacokinetics of diclofenac sodium following intravenous and oral administration

Willis, J. V., Kendall, M. J., Flinn, R. M., Thornhill, D. P., & Welling, P. G. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00568201 · Cited by 269

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin

Hoffman, W. F., Alberts, A. W., Anderson, P. S., Chen, J. S., Smith, R. L., & Willard, A. K. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00155a040 · Cited by 266

Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A Reductase

ENDO, A., TSUJITA, Y., KURODA, M., & TANZAWA, K. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11637.x · Cited by 262

Chemical differentiation of histamine H1- and H2-receptor agonists

Durant, G. J., Ganellin, C. R., & Parsons, M. E. (1975) · Journal of Medicinal Chemistry · doi:10.1021/jm00243a009 · Cited by 259

Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents

Besancon, M., Simon, A., Sachs, G., & Shin, J. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22438 · Cited by 259

Asymmetric synthesis of esomeprazole

Cotton, H., Elebring, T., Larsson, M., Li, L., Sörensen, H., & von Unge, S. (2000) · Tetrahedron: Asymmetry · doi:10.1016/s0957-4166(00)00352-9 · Cited by 251

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. B. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 247

Critical review of the role of HTS in drug discovery

Macarron, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241

Hydrophobic Interactions

Némethy, G. (1967) · Angewandte Chemie International Edition in English · doi:10.1002/anie.196701951 · Cited by 232

DNA and RNA Synthesis: Antifolates

Kompis, I. M., Islam, K., & Then, R. L. (2005) · Chemical Reviews · doi:10.1021/cr0301144 · Cited by 231

Adrenaline-Forming Enzyme in Brainstem: Elevation in Genetic and Experimental Hypertension

Saavedra, J. M., Grobecker, H., & Axelrod, J. (1976) · Science · doi:10.1126/science.1246633 · Cited by 223

N-[[(5-Methyl-3-phenylisoxazol-4-yl)- phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration

Talley, J. J., Bertenshaw, S. R., Brown, D. L., Carter, J. S., Graneto, M. J., Kellogg, M. S., Koboldt, C. M., Yuan, J., Zhang, Y. Y., & Seibert, K. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000069h · Cited by 213

Omeprazole: The first proton pump inhibitor

Lindberg, P., Brändström, A., Wallmark, B., Mattsson, H., Rikner, L., & Hoffmann, K. (1990) · Medicinal Research Reviews · doi:10.1002/med.2610100102 · Cited by 213

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Tobert, J. A., Bell, G. D., Birtwell, J., James, I., Kukovetz, W. R., Pryor, J. S., Buntinx, A., Holmes, I. B., Chao, Y. S., & Bolognese, J. A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110530 · Cited by 202

Selective Optimization of Side Activities: Another Way for Drug Discovery

Wermuth, C. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030480f · Cited by 201

Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy

Steinberg, D. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600009-jlr200 · Cited by 200

METHYLATION OF NICOTINAMIDE WITH A SOLUBLE ENZYME SYSTEM FROM RAT LIVER

Cantoni, G. L. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56110-x · Cited by 196

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.

Rustum, Y. M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M. B., Wilke, H., & Seeber, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.389 · Cited by 192

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

Bartlett, R. R., Dimitrijevic, M., Mattar, T., Zielinski, T., Germann, T., Rüde, E., Thoenes, G. H., Küchle, C. C. A., Schorlemmer, H. U., Bremer, E., et al. (1991) · Agents and Actions · doi:10.1007/bf01983301 · Cited by 189

Drug permeation in biomembranes

Mälkiä, A., Murtomäki, L., Urtti, A., & Kontturi, K. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.05.009 · Cited by 186

Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes

Mignat, C., Wille, U., & Ziegler, A. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00010-4 · Cited by 179

Comparison of Nine Programs Predicting p Ka Values of Pharmaceutical Substances

Liao, C., & Nicklaus, M. C. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900289x · Cited by 179

Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers

Tse, F. L. S., Jaffe, J. M., & Troendle, A. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb05773.x · Cited by 175

Thymidylate synthase inhibitors as anticancer agents: from bench to bedside

Chu, E., Callender, M. A., Farrell, M. P., & Schmitz, J. C. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0625-9 · Cited by 174

Metabolism of Thiopyrimidines and Thiopurines

Remy, C. N. (1963) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81262-5 · Cited by 172

The Biochemistry of Drug Metabolism – An Introduction: Part 2. Redox Reactions and Their Enzymes

Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790032 · Cited by 171

Therapeutic Response to Lovastatin (Mevinolin) in Nonfamilial Hypercholesterolemia: A Multicenter Study

(1986) · JAMA · doi:10.1001/jama.1986.03380200067023 · Cited by 168

Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors

Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., & Hirai, K. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00248-9 · Cited by 167

Therapeutic response to lovasatain (Mevinolin) in nonfamilial hypercholesterolemia - A Multicenter study

Hunninghake, D. B., Larose, J., Palmer, R. H., & Leon, A. S. (1986) · JAMA · Cited by 166

Lipophilicity in Molecular Modeling

Testa, B., Carrupt, P.-A., Gaillard, P., Billois, F., & Weber, P. (1996) · Pharmaceutical Research · doi:10.1023/a:1016024005429 · Cited by 163

Physiologically Based Pharmacokinetic (PBPK) Modeling of Caffeine and Theophylline in Neonates and Adults: Implications for Assessing Children's Risks from Environmental Agents

Ginsberg, G., Hattis, D., Russ, A., & Sonawane, B. (2004) · Journal of Toxicology and Environmental Health, Part A · doi:10.1080/15287390490273550 · Cited by 161

Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor

Tang, C., Shou, M., Mei, Q., Rushmore, T. H., & Rodrigues, A. D. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39255-9 · Cited by 159

Precursors of adrenal epinephrine and norepinephrine in vivo

Udenfriend, S., & Wyngaarden, J. B. (1956) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(56)90261-x · Cited by 158

A Model for Human Cytochrome P450 2D6 Based on Homology Modeling and NMR Studies of Substrate Binding

Modi, S. P., Paine, M. J. I., Sutcliffe, M. J., Lian, L., Primrose, W. U., Wolf, C. R., & Roberts, G. C. K. (1996) · Biochemistry · doi:10.1021/bi952742o · Cited by 153

New assay technologies for high-throughput screening

Silverman, L., Campbell, R., & Broach, J. R. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80015-x · Cited by 151

Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N., & Traxler, P. M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00197-7 · Cited by 150

Design and Discovery of Small Molecules Targeting Raf-1 Kinase

Lowinger, T. B., Riedl, B., Dumas, J., & Smith, R. A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 150

Selective optimization of side activities: the SOSA approach

Wermuth, C. G. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03686-x · Cited by 144

Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s.

Imaoka, S., Enomoto, K., Oda, Y., Asada, A., Fujimori, M., Shimada, T., Fujita, S., Guengerich, F. P., & Funae, Y. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23210-4 · Cited by 141

Lovastatin: A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Use in Hyperlipidaemia

Henwood, J. M., & Heel, R. C. (1988) · Drugs · doi:10.2165/00003495-198836040-00003 · Cited by 138

Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell

Wallmark, B., Brändström, A., & Larsson, H. (1984) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(84)90406-1 · Cited by 136

The Nobel Chronicles

Raju, T. N. K. (2000) · The Lancet · doi:10.1016/s0140-6736(05)74775-9 · Cited by 133

Conversion of Prostaglandin G/H Synthase-1 into an Enzyme Sensitive to PGHS-2-selective Inhibitors by a Double His513→ Arg and Ile523→ Val Mutation

Wong, E., Bayly, C. I., Waterman, H. L., Riendeau, D., & Mancini, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.14.9280 · Cited by 131

Esomeprazole

Spencer, C. M., & Faulds, D. M. (2000) · Drugs · doi:10.2165/00003495-200060020-00006 · Cited by 127

Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2

Esser, R. E., Berry, C., Du, Z., Dawson, J., Fox, A., Fujimoto, R. A., Haston, W. O., Kimble, E. F., Koehler, J., Peppard, J., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706078 · Cited by 125

Enzymic methylation of foreign sulfhydryl compounds

Bremer, J., & Greenberg, D. M. (1961) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(61)90746-6 · Cited by 122

IN VITRO METABOLISM STUDIES ON THE ISOXAZOLE RING SCISSION IN THE ANTI-INFLAMMATORY AGENT LEFLUNOMIDE TO ITS ACTIVE α-CYANOENOL METABOLITE A771726: MECHANISTIC SIMILARITIES WITH THE CYTOCHROME P450-CATALYZED DEHYDRATION OF ALDOXIMES

Kalgutkar, A. S. S., Hang, N. T. T., Vaz, A. D. N., Doan, A., Dalvie, D., McLeod, D., & Murray, J. C. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1240 · Cited by 118

Crystal Structure of S-Adenosylmethionine Synthetase

Takusagawa, F., Kamitori, S., Misaki, S., & Markham, G. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.1.136 · Cited by 117

Diclofenac sodium (GP 45840, voltaren), a potent inhibitor of prostaglandin synthetase

Ku, E. C., Wsvary, J. M., & Cash, W. D. (1975) · Biochemical Pharmacology · doi:10.1016/0006-2952(75)90186-0 · Cited by 114

Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines

Shelley, M. D., Hartley, L., Fish, R. G., Groundwater, P. W., Morgan, J. J. G., Mort, D., Mason, M., & Evans, A. R. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00302-4 · Cited by 112

In VitroMetabolism and Covalent Binding of Enol-Carboxamide Derivatives and Anti-Inflammatory Agents Sudoxicam and Meloxicam: Insights into the Hepatotoxicity of Sudoxicam

Obach, R. S., Kalgutkar, A. S. S., Ryder, T. F., & Walker, G. S. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800185b · Cited by 111

Hormonal Therapy of Male Hypogonadism

Matsumoto, A. M. (1994) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30072-0 · Cited by 110

A New, Active Metabolite of ‘Miracil D’

Rosi, D., Peruzzotti, G. P., Dennis, E. W., Berberian, D. A., Freele, H., & Archer, S. (1965) · Nature · doi:10.1038/2081005a0 · Cited by 105

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

Strumberg, D., Voliotis, D., Moeller, J.-G., Hilger, R. A., Richly, H., Kredtke, S., Beling, C., Scheulen, M. E., & Seeber, S. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40580 · Cited by 104

Systemic analgesic activity and .delta.-opioid selectivity in [2,6-dimethyl-Tyr1, D-Pen2, D-Pen5]enkephalin

Hansen, D. W., Stapelfeld, A., Savage, M. A., Reichman, M., Hammond, D. L., Haaseth, R. C., & Mosberg, H. I. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00082a008 · Cited by 101

Crystal Structure of the S-Adenosylmethionine Synthetase Ternary Complex: A Novel Catalytic Mechanism of S-Adenosylmethionine Synthesis from ATP and Met,

Komoto, J., Yamada, T., Takata, Y., Markham, G. D., & Takusagawa, F. (2004) · Biochemistry · doi:10.1021/bi035611t · Cited by 100

Molecular Mechanisms Controlling the Rate and Specificity of Catechol O-Methylation by Human Soluble Catechol O-Methyltransferase

Lautala, P., Ulmanen, I., & Taskinen, J. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12851-9 · Cited by 96

CNS drug delivery: Opioid peptides and the blood-brain barrier

WITT, K. A., & Davis, T. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080109 · Cited by 95

Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half‐life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers

Galmiche, J., Varannes, S. B. D., Ducrotte, P. R., Sacher‐Huvelin, S., Vavasseur, F., Taccoen, A., Fiorentini, P., & Homerin, M. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01893.x · Cited by 91

Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans.

Liu, Y., Toubro, S., Astrup, A. V., & Stock, M. J. (1995) · PubMed · Cited by 89

Role of epinephrine in acute stress

Wortsman, J. (2002) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(01)00024-x · Cited by 88

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

Bocan, T. M. A., Ferguson, E., McNally, W. P., Uhlendorf, P. D., Mueller, S. B., DeHart, P. D., Sliskovic, D. R., Roth, B. D., Krause, B. R., & Newton, R. S. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90103-3 · Cited by 85

Molecular recognition of opioid receptor ligands

Kane, B. E., Svensson, B., & Ferguson, D. M. (2006) · The AAPS Journal · doi:10.1208/aapsj080115 · Cited by 85

New metabolic pathways of alpha-lipoic acid.

Schupke, H., Hempel, R., Peter, G., Hermann, R., Wessel, K., Engel, J., & Kronbach, T. (2001) · PubMed · Cited by 78

Comparison of the effects of D‐(‐)‐ephedrine and L‐(+)‐pseudoephedrine on the cardiovascular and respiratory systems in man.

Drew, C. D. M., Knight, G. C., Hughes, D. T. D., & Bush, M. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb04588.x · Cited by 76

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted-[1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives

Stokker, G. E., Alberts, A. W., Anderson, P., et al. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00152a002 · Cited by 68

Letter: Gentamicin-resistant Pseudomonas aeruginosa.

Rd, M. (1976) · PubMed · Cited by 65

Immunochemical Identification of Mouse Hepatic Protein Adducts Derived from the Nonsteroidal Anti-Inflammatory Drugs Diclofenac, Sulindac, and Ibuprofen

Wade, L. T., Kenna, J. G., & Caldwell, J. (1997) · Chemical Research in Toxicology · doi:10.1021/tx960153t · Cited by 62

Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase

Erlandsson, P. G., Isaksson, R., Lorentzon, P., & Lindberg, P. (1990) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83781-0 · Cited by 61

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

Shaw, M. K., Newton, R. S., Sliskovic, D. R., Roth, B. D., Ferguson, E., & Krause, B. R. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)92151-o · Cited by 54

Riboflavin Deficiency and Iron Absorption in Adult Gambian Men

Fairweather‐Tait, S. J., Powers, H. J., MINSKI, M. J., Whitehead, J. S. W., & Downes, R. (1992) · Annals of Nutrition and Metabolism · doi:10.1159/000177696 · Cited by 49

Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays

Cromlish, W. A., & Kennedy, B. P. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00599-0 · Cited by 48

Disposition of fluvastatin, an inhibitor of HMG‐CoA reductase, in mouse, rat, dog, and monkey

Tse, F. L. S., Smith, H. T., Ballard, F. H., & Nicoletti, J. M. (1990) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510110606 · Cited by 45

Exploration of the Pharmacophore of 3-Alkyl-5-Arylimidazolidinediones as New CB1Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling

Ooms, F., Wouters, J., Oscari, O., Happaerts, T., Bouchard, G., Carrupt, P., Testa, B., & Lambert, D. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010896y · Cited by 43

EFFECT OF THE NEW HMG-CoA REDUCTASE INHIBITOR CERIVASTATIN (BAY W 6228) ON MIGRATION, PROLIFERATION AND CHOLESTEROL SYNTHESIS IN ARTERIAL MYOCYTES

Corsini, A. (1996) · Pharmacological Research · doi:10.1006/phrs.1996.0009 · Cited by 42

The Role of Permeability in Drug ADME/PK, Interactions and Toxicity—Presentation of a Permeability-Based Classification System (PCS) for Prediction of ADME/PK in Humans

Fagerholm, U. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9397-y · Cited by 41

Phenol-O-methyltransferase

Axelrod, J., & Daly, J. W. (1968) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(68)90131-9 · Cited by 40

Continuing development of acid pump inhibitors: site of action of pantoprazole.

Shin, J., Besancon, M., Prinz, C., et al. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00211.x · Cited by 38

Biosynthesis and characterization of (S)-and (R)-3-hydroxy-3-methylglutaryl coenzyme A

Bischoff, K. M., & Rodwell, V. W. (1992) · Biochemical Medicine and Metabolic Biology · doi:10.1016/0885-4505(92)90060-c · Cited by 28

The Long-lasting Effect of TU-199, a Novel H+,K+-ATPase Inhibitor, on Gastric Acid Secretion in Dogs

Uchiyama, K., Wakatsuki, D., Kakinoki, B., Takeuchi, Y., Araki, T., & Morinaka, Y. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772510 · Cited by 26

Esomeprazole in the Framework of Proton‐Pump Inhibitor Development

Lindberg, P., & Carlsson, E. I. (2006) · doi:10.1002/3527608001.ch5 · Cited by 16

Drug Discovery, Design, and Development

Silverman, R. B. (2004) · Elsevier eBooks · doi:10.1016/b978-0-08-051337-9.50007-9 · Cited by 15

SC-46275: a potent, long-acting gastric antisecretory prostaglandin with low oral bioavailability in the dog.

Perkins, W. E., Burton, E. G., Tsai, B. S., Collins, P. W., Casler, J. J., Gasiecki, A. F., Bauer, R. F., Jones, P. H., & Gaginella, T. S. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20442-6 · Cited by 7

Drug Metabolism

Silverman, R. B. (2004) · Elsevier eBooks · doi:10.1016/b978-0-08-051337-9.50012-2 · Cited by 6